Management Team:
Liqun Wang, Ph.D, MBA
Founder & Chief Executive Officer
Liqun has over 25 years of professional experience in Europe in healthcare and finance. She has held senior positions in GlaxoSmithkline, Novatis and BSI Bank, leading global departments that consist of senior professionals of multi-nationalities. For the last 10 years, she is active in private equity investments and cross border M&A advisory.
Theobald Brun, Ph.D in law
Legal Counsel
Theo is an experienced Swiss attorney and public Notary. He is also the Chairman of Ticino Chapter of Swiss Chinese Chamber of Commerce. Apart from general law and litigation work, he specialises also in Law in Art and holds qualifications in fiduciary management.
Feng Lu-Pagenkopf, Dr. -Ing.
Partner & Secretary General
Feng is an architect specialized in sustainable city planning. As early as the 90’s, she has engaged in academic research in Europe in the area of innovative solutions for sustainable city development in China and worked as a senior advisor for Siemens and Hannover Expo 2000. In the last 5 years, She has successfully managed a series of cross border exchange projects in healthcare, banking and sustainable designs.
Partners:
Kevin Chen, Ph.D
Kevin is an experienced life science executive and entrepreneur. After a decade spent in USA first for his doctoral study in University of Minnesota and then research at Massachusetts Institute of Technology (MIT) and California Institute of Technology(CalTech), he returned to China in 1997 as the Director of R&D Centre, Novo Nordisk China. He was co-founder of Innovent Biologics Inc, and Rugen Therapeutics R&D (Shanghai), both of which are innovative biotechnology companies in China with funding from leading venture funds such as Fidelity, Lilly Venture, Bioveda, and Suzhou industrial Park (SIP) Ventures. He founded and built up BioDuro, a biomedical research organisation in Shanghai, between 2007-2009. Kevin is a member of Biotech Strategic Planning Committee with the Shanghai National Development and Reform Commission. He is also a senior consultant to PuDong New District government for the development of biomedical Industry in Shanghai, China.
Stefano De Marchis, JD in law, MBA
Stefano is a senior figure in major Italian corporations for over 25 years. He has held positions such as Siemens Stet CEO for Italy, CIO for RCS Media Group, COO of UBI Bank. All those companies are leading public companies listed on the Milan Stock Exchange. He was also COO of Europe Division for TRW Financial Services, a US headquartered multinational financial services group.
Stefano holds a JD in Law from University of Rome in Italy and a MBA from Stanford University in USA. He is also a visiting professor of Economics and Business at the Catholic University of Sacro Cuore in Milan, Italy.
Gerhard Ries, PhD
Gerhard is Founder & Managing Partners of LifeCare Partners, a dedicated venture capital and private equity firm in the European healthcare sector. Gerhard has more than 20 years of global pharma industry and venture capital experience as both entrepreneur and investor. He supervised more than 50 investments in life science companies and served on the board of more than 20 companies, including 4-Antibody, Activaero, Affimed, Curetis, Delenex, Develco Pharma, Esbatech, Eyesense, Glycart, Lipomed, Vaximm, etc.. Gerhard has strong scientific and operational background and held various corporate positions at McKinsey, Novartis, Ciba Geigy, Boehringer Mannheim and was Co-founder and Managing Partner of BioMedPartners. Gerhard holds a M.S. and a Ph.D. degree in Molecular Biology from the University of Basel and a M.S. degree in Biotechnology from the Fachhochschule Weihenstephan (Munich). Gerhard's current board representations include DiaMedCare, Devis Pharma, Kuros, Biosciences, Leon Nanodrugs and Xeltis.
Shuai Yang, Master in Pharmaceutical Sciences
Shuai Yang is an experienced investment banker in healthcare sector. She has held positions such as a senior analyst in healthcare sector with one of the top securities firms in China for many years and senior investment manager with a family investment fund. In 2013 she ranked number 4 top analyst in all China security industry for the biopharmaceutical sector.
Shuai Yang holds a Master in Pharmaceutical Siences from Peking Union Medical School.
Advisors:
Marco Londei M.D.
Marco is a specialist in gastroentrology and immunology. He has been Professor of Medicine at Imperial College and University College London, UK. Marco has made seminal contributions in the field inflammation, autoimmunity and immunology. He has extensively published in the leading scientific and medical journals such as Science, Nature, The Lancet and PNAS. He holds several patents for the treatment of inflammatory diseases. After his academic experience he joined the pharmaceutical industry as a senior executive, leading the transition of new molecular entities into patients. Marco, and the team he led, have designed and performed the clinical studies that led to progression from early clinical development to approval of six innovative medicines.
